Relieving the Pressure in Hypertrophic Cardiomyopathy

This session presents different approaches to treating patients with hypertrophic cardiomyopathy (HCM). Topics to be covered include when to consider treatment to reduce LV outflow tract gradients, using new and emerging pharmacologic strategies as well as surgical and non-surgical ablation therapies.

Agenda

Moderator - Kia Afshar, MD

• Moderator - Milind Desai, MD
• What Gradient Is Needed to Justify Treatment in HCM? - Richard Carrick, MD, PhD
• Cardiac Myosin Inhibition: Risks and Benefits - Andrew Willeford, PharmD, PhD, BCCP
• Surgery vs. Non-Surgical Septal Reduction - Andrew Wang, MD
• Non-Sarcomeric HCM - Alejandro De Feria, MD
• Is It Safe to Exercise with HCM? - Theodore Abraham, MD
• Panel Discussion / Audience Q&A